In the case of United States v. Chas. Pfizer & Co., Inc., et al, 1971, the U.S Supreme Court dealt with an antitrust lawsuit filed by the government against several pharmaceutical companies including Pfizer and Squibb. The government alleged that these firms had conspired to fix prices on tetracycline, a broad-spectrum antibiotic drug in violation of Sherman Act which prohibits certain business activities deemed as anti-competitive or monopolistic. However, the District Court dismissed this claim stating that it was based on speculation and conjecture rather than concrete evidence. The Supreme Court reversed this decision upon appeal arguing that there was substantial circumstantial evidence pointing towards collusion among these companies to control tetracycline prices despite each company having its own patent for producing different strains of tetracycline bacteria. This included identical pricing structures across all defendants and simultaneous price increases despite differences in production costs. The court held that while direct proof of conspiracy is not always necessary under antitrust laws; sufficient circumstantial evidence can be used to infer such agreements especially when they lead towards unnatural parallel business behavior among competitors.

The dissenting opinion in the case of United States v. Chas. Pfizer & Co., Inc., et al, argued that the majority's decision to find an illegal price-fixing conspiracy was based on insufficient evidence and a misinterpretation of antitrust laws. The dissent contended that mere parallel pricing behavior among competitors should not be enough to establish a violation of Sherman Act Section 1 without clear proof of explicit agreement or collusion between them. It further stated that such business practices could simply reflect independent responses to similar market conditions rather than conspiratorial conduct, and thus it would be unjust to penalize companies for merely adapting their prices according to competitive market forces. Moreover, the dissent expressed concern about potential chilling effects on legitimate competition if businesses had to constantly fear being accused of illegal conspiracies due solely based on circumstantial evidence like identical pricing strategies.